Circulating Tumor DNA Dynamics as Early Outcome Predictors for Lisocabtagene Maraleucel as Second-Line Therapy for Large B-Cell Lymphoma from the Phase 3 TRANSFORM Study

Background: While the prognostic value of MRD using ultrasensitive circulating tumor DNA (ctDNA) assays after first-line immunochemotherapy for DLBCL has been shown (Roschewski M, et al. Blood 2022;140[suppl 1]:785), its relevance to outcomes after second-line (2L) treatment with CD19-directed CAR T...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Blood 2023-11, Vol.142 (Supplement 1), p.225-225
Hauptverfasser:	Stepan, Lara, Ansari, Sahar, Okal, Abood, Dell'Aringa, Justine, Thompson, Ethan, Crotta, Alessandro, Chow, Victor A, Abramson, Jeremy S., Kamdar, Manali, Chabon, Jacob J., Hogan, Gregory, Kurtz, David M., Alizadeh, Ash A., Peiser, Leanne
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!